A Phase 3 interventional study of Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg and Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 35 sites in Japan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-01-11.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline — 7 open to participants now, 8 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · GlaxoSmithKline.
Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 97th largest by enrollment of the 236 interventional ones that give a count, is one of 22 that started in 2010, is one of 65 in phase 3, and was the 94th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →7 of the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Argentina
Ages 40–80
GlaxoSmithKline · Sites in United States, Japan
Ages 40–80
GlaxoSmithKline · Sites in United Kingdom
Ages 18–55 · Healthy volunteers
GlaxoSmithKline · Sites in United States, Australia, Bulgaria and 10 more countries
Ages 40–75
GlaxoSmithKline · Sites in United States, Argentina, Australia and 13 more countries
Ages 40–80
By country, each count listing its studies:
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
276 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 84 · Phase 2 47 · Phase 3 65 · Phase 4 38
First in 2000; this study’s year is marked. 22 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 187 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 101 across the 236 interventional studies, 1,248 across the 40 observational. Of the 264 that completed or were terminated, 141 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
2 of the studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06154837GlaxoSmithKlineA Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease | 2026-12-16 |
| NCT07789899GlaxoSmithKlineA Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants | 2027-09-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of the study is to evaluate the safety and tolerability of fluticasone furoate/GW642444 inhalation powder when administered once-daily for 52 weeks in Japanese patients with COPD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination inhaled corticosteroid and long-acting beta2-agonist
Drug: Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg
Combination inhaled corticosteroid and long-acting beta2-agonist
Drug: Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg
Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold \>=5%) and SAEs.
Time frame: From the start of investigational product to the last dose of treatment (up to Week 52/Withdrawal [WD])
Number of Participants With Any Drug-related AE and Any Drug-related SAE Throughout the Treatment Period
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. Relatedness was assessed by the investigator.
Time frame: From the start of investigational product to the last dose of treatment (up to Week 52/Withdrawal [WD])
Number of Participants With Pneumonia During the Treatment Period
Pneumonia is an inflammatory condition of the lung, affecting primarily the microscopic air sacs known as alveoli. All diagnoses of pneumonia (radiographically confirmed or unconfirmed) were reported as an AE or SAE. An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the ot
Time frame: From the start of investigational product to the last dose of treatment (up to Week 52/Withdrawal [WD])
Number of Participants for the Indicated Hematological Parameters Who Experienced Low, Normal, and High Levels at Baseline (BL) and Week 52/Withdrawal (WD)
Hematological parameters included: Basophils (Baso), Eosinophils (Eosin), Lymphocytes (Lymph), Monocytes (Mono), Total Neutrophils (TN), Hemoglobin (Hemo), Hematocrit (Hmcrt), Platelet Count (PT), Red Blood Cell Count (RBC Count), White Blood Cell Count (WBC Count). Data are reported as the number of participants who had low, normal, and high levels at BL (Week-2) and Week 52/WD.
Time frame: Baseline (Week -2), and Week 52/Withdrawal (WD)
Number of Participants for the Indicated Clinical Chemistry and Urinalysis Parameters Who Experienced a Low, Normal, and High Levels at Baseline (BL) and Week 52/Withdrawal (WD)
Clinical chemistry and urinalysis parameters included: Albumin, Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Bilirubin (Direct \[BD\], Indirect \[BI\], and Total \[BT\]), Creatine Kinase (CK), Chloride, Carbon Dioxide content/Bicarbonate (CO2/BC), Creatinine, Gamma Glutamyl Transferase (GGT), Glucose, Potassium, Lactate Dehydrogenase (LDH), Sodium, Urine pH, Urine Specific Gravity (USG),Total Protein (TP), Urea/Blood urea nitrogen (BUN), and Uric Acid (UA). Data are reported as the number of participants who had low, normal, and high levels at BL (Week-2) and Week 52/WD.
Time frame: Baseline (Week -2), and Week 52/Withdrawal (WD
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline (BL) and Week 52/Withdrawal (WD)
Urinalysis parameters included: Urine Occult Blood (UOB), Urine Glucose (UG), Urine Ketones (UK), Urine Protein (UP), and Urine Leukocyte Esterase test for detecting White Blood Cell (UWBC). The dipstick was a strip used to detect the presence or absence of these parameters in the urine sample. The dipstick test gives results in a semi-quantitative manner, and results can be read as negative (Neg), Trace, 1+, 2+, and 3+, indicating proportional concentrations in the urine sample. Data are reported as the number of participants who had neg, trace, 1+, 2+, and 3+ levels at Baseline (Week -2) and Week 52/WD.
Time frame: Baseline (Week -2), Week 52/Withdrawal (WD)
Change From Baseline in 24-hour Urinary Cortisol Excretion at Weeks 24 and 52/Withdrawal (WD)
24-hour urinary cortisol excretion was calculated by multiplying the total volume of urine by the concentration of urinary cortisol. Cortisol is a hormone released from the adrenal gland that helps in fat, protein, and carbohydrate metabolism. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline (Week 0), Week 24, and Week 52/Withdrawal (WD)
Change From Baseline in Blood Pressure at Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD
Blood pressure measurement included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD. Blood pressure was measured in a sitting position after a participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline (Week 0), Week 4, Week 8, Week 12, Week 16, Week 24, Week 32, Week 40, Week 52, Week 24/WD, and Week 52/WD
Change From Baseline in Heart Rate (HR) at Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD
Heart rate was measured in a sitting position after a participant was kept at rest for at least 5 minutes at assessment time points (Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline (Week 0), Week 4, Week 8, Week 12, Week 16, Week 24, Week 32, Week 40, Week 52, Week 24/WD, Week 52/WD
Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings
A 12-lead ECG was recorded in a supine position after the participant was kept at rest in this position for at least 5 minutes at assessment time points (Week 12, Week 24, and Week52). Data are presented for clinically significant (CS) as well as not clinically significant (NCS) abnormal findings. Any abnormal ECG, including those that worsen from baseline, and clinically significant as assessed by the investigator were recorded as CS.
Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52
| Milestone | FF/VI 100/25 µg | FF/VI 200/25 µg |
|---|---|---|
| Started | 60 | 127 |
| Completed | 49 | 106 |
| Not completed | 11 | 21 |
| Withdrew: Adverse event | 7 | 12 |
| Withdrew: Participants reached stopping criteria | 3 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 6 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold \>=5%) and SAEs.
| Participants | FF/VI 100/25 µg | FF/VI 200/25 µg |
|---|---|---|
| Any Non-serious AE | 36 | 93 |
| Any SAE | 10 | 23 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. Relatedness was assessed by the investigator.
| Participants | FF/VI 100/25 µg | FF/VI 200/25 µg |
|---|---|---|
| Any AE | 12 | 30 |
| Any SAE | 1 | 2 |
Pneumonia is an inflammatory condition of the lung, affecting primarily the microscopic air sacs known as alveoli. All diagnoses of pneumonia (radiographically confirmed or unconfirmed) were reported as an AE or SAE. An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the ot
| Participants | FF/VI 100/25 µg | FF/VI 200/25 µg |
|---|---|---|
| Pneumonia recorded as an AE | 6 | 19 |
| Pneumonia recorded as an SAE | 4 | 9 |
Hematological parameters included: Basophils (Baso), Eosinophils (Eosin), Lymphocytes (Lymph), Monocytes (Mono), Total Neutrophils (TN), Hemoglobin (Hemo), Hematocrit (Hmcrt), Platelet Count (PT), Red Blood Cell Count (RBC Count), White Blood Cell Count (WBC Count). Data are reported as the number of participants who had low, normal, and high levels at BL (Week-2) and Week 52/WD.
| Participants | FF/VI 100/25 µg | FF/VI 200/25 µg |
|---|---|---|
| Baso, High, BL, n=60, 127 | 2 | 0 |
| Baso, Normal, BL, n= 60, 127 | 58 | 127 |
| Baso, Low, BL, n= 60, 127 | 0 | 0 |
| Baso, High, Week 52/WD, n=56, 122 | 1 | 1 |
| Baso, Normal, Week 52/WD, n=56, 122 | 55 | 121 |
| Baso, Low, Week 52/WD n=56, 122 | 0 | 0 |
| Eosin, High, BL, n=60, 127 | 5 | 15 |
| Eosin, Normal, BL, n=60, 127 | 55 | 112 |
| Eosin, Low, BL, n=60, 127 | 0 | 0 |
| Eosin, High, Week 52/WD, n=56, 122 | 5 | 11 |
| Eosin, Normal, Week 52/WD, n=56, 122 | 51 | 111 |
| Eosin, Low, Week 52/WD, n=56, 122 | 0 | 0 |
| Lymph, High, BL, n=60, 127 | 1 | 1 |
| Lymph, Normal, BL, n=60, 127 | 58 | 121 |
| Lymph, Low, BL, n=60, 127 | 1 | 5 |
| Lymph, High, Week 52/WD, n=56, 122 | 0 | 0 |
| Lymph, Normal, Week 52/WD, n=56, 122 | 51 | 108 |
| Lymph, Low, Week 52/WD, n=56, 122 | 5 | 14 |
| Mono, High, BL, n=60, 127 | 9 | 8 |
| Mono, Normal, BL, n=60, 127 | 51 | 119 |
| Mono, Low, BL, n=60, 127 | 0 | 0 |
| Mono, High, Week 52/WD, n=56, 122 | 7 | 14 |
| Mono, Normal, Week 52/WD, n=56, 122 | 49 | 108 |
| Mono, Low, Week 52/WD, n=56, 122 | 0 | 0 |
| TN, High, BL, n=60, 127 | 0 | 5 |
| TN, Normal, BL, n=60, 127 | 58 | 119 |
| TN, Low, BL, n=60, 127 | 2 | 3 |
| TN, High, Week 52/WD, n=56, 122 | 4 | 11 |
| TN, Normal, Week 52/WD, n=56, 122 | 52 | 111 |
| TN, Low, Week 52/WD, n=56, 122 | 0 | 0 |
| Hemo, High, BL, n=60, 127 | 1 | 2 |
| Hemo, Normal, BL, n=60, 127 | 48 | 112 |
| Hemo, Low, BL, n=60, 127 | 11 | 13 |
| Hemo, High, Week 52/WD, n=56, 122 | 0 | 0 |
| Hemo, Normal, Week 52/WD, n=56, 122 | 45 | 108 |
| Hemo, Low, Week 52/WD, n=56, 122 | 11 | 14 |
| Hmcrt, High, BL, n=60, 127 | 4 | 13 |
| Hmcrt, Normal, BL, n=60, 127 | 50 | 110 |
| Hmcrt, Low, BL, n=60, 127 | 6 | 4 |
| Hmcrt, High, Week 52/WD, n=56, 122 | 1 | 8 |
| Hmcrt, Normal, Week 52/WD, n=56, 122 | 50 | 106 |
| Hmcrt, Low, Week 52/WD, n=56, 122 | 5 | 8 |
| PT, High, BL, n=60, 127 | 1 | 0 |
| PT, Normal, BL, n=60, 127 | 57 | 124 |
| PT, Low, BL, n=60, 127 | 2 | 3 |
| PT, High, Week 52/WD, n=56, 122 | 2 | 4 |
| PT, Normal, Week 52/WD, n=56, 122 | 51 | 116 |
| PT, Low, Week 52/WD, n=56, 122 | 3 | 2 |
| RBC Count, High, BL, n=60, 127 | 0 | 4 |
| RBC Count, Normal, BL, n=60, 127 | 53 | 111 |
| RBC Count, Low, BL, n=60, 127 | 7 | 12 |
| RBC Count, High, Week 52/WD, n=56, 122 | 0 | 2 |
| RBC Count, Normal, Week 52/WD, n=56, 122 | 47 | 107 |
| RBC Count, Low, Week 52/WD, n=56, 122 | 9 | 13 |
| WBC Count, High, BL, n=60, 127 | 2 | 6 |
| WBC Count, Normal, BL, n=60, 127 | 57 | 119 |
| WBC Count, Low, BL, n=60, 127 | 1 | 2 |
| WBC Count, High, Week 52/WD, n=56, 122 | 3 | 4 |
| WBC Count, Normal, Week 52/WD, n=56, 122 | 52 | 116 |
| WBC Count, Low, Week 52/WD, n=56, 122 | 1 | 2 |
Clinical chemistry and urinalysis parameters included: Albumin, Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Bilirubin (Direct \[BD\], Indirect \[BI\], and Total \[BT\]), Creatine Kinase (CK), Chloride, Carbon Dioxide content/Bicarbonate (CO2/BC), Creatinine, Gamma Glutamyl Transferase (GGT), Glucose, Potassium, Lactate Dehydrogenase (LDH), Sodium, Urine pH, Urine Specific Gravity (USG),Total Protein (TP), Urea/Blood urea nitrogen (BUN), and Uric Acid (UA). Data are reported as the number of participants who had low, normal, and high levels at BL (Week-2) and Week 52/WD.
| Participants | FF/VI 100/25 µg | FF/VI 200/25 µg |
|---|---|---|
| Albumin, High, BL, n=60, 127 | 0 | 2 |
| Albumin, Normal, BL, n=60, 127 | 56 | 112 |
| Albumin, Low, BL, n=60, 127 | 4 | 13 |
| Albumin, High, Week 52/WD, n=56, 122 | 0 | 1 |
| Albumin, Normal, Week 52/WD, n=56, 122 | 49 | 99 |
| Albumin, Low, Week 52/WD, n=56, 122 | 7 | 22 |
| AP, High, BL, n=60, 127 | 4 | 10 |
| AP, Normal, BL, n=60, 127 | 56 | 117 |
| AP, Low, BL, n=60, 127 | 0 | 0 |
| AP, High, Week 52/WD, n=56, 122 | 5 | 6 |
| AP, Normal, Week 52/WD, n=56, 122 | 51 | 116 |
| AP, Low, Week 52/WD, n=56, 122 | 0 | 0 |
| ALT, High, BL, n=60, 127 | 4 | 9 |
| ALT, Normal, BL, n=60, 127 | 56 | 117 |
| ALT, Low, BL, n=60, 127 | 0 | 1 |
| ALT, High, Week 52/WD, n=56, 122 | 4 | 6 |
| ALT, Normal, Week 52/WD, n=56, 122 | 52 | 116 |
| ALT, Low, Week 52/WD, n=56, 122 | 0 | 0 |
| AST, High, BL, n=60, 127 | 5 | 11 |
| AST, Normal, BL, n=60, 127 | 55 | 116 |
| AST, Low, BL, n=60, 127 | 0 | 0 |
| AST, High, Week 52/WD, n=56, 122 | 3 | 5 |
| AST, Normal, Week 52/WD, n=56, 122 | 53 | 117 |
| AST, Low, Week 52/WD, n=56, 122 | 0 | 0 |
| BD, High, BL, n=60, 127 | 7 | 4 |
| BD, Normal, BL, n=60, 127 | 53 | 123 |
| BD, Low, BL, n=60, 127 | 0 | 0 |
| BD, High, Week 52/WD, n=56, 122 | 3 | 4 |
| BD, Normal, Week 52/WD, n=56, 122 | 53 | 118 |
| BD, Low, Week 52/WD, n=56, 122 | 0 | 0 |
| BI, High, BL, n=60, 127 | 4 | 1 |
| BI, Normal, BL, n=60, 127 | 56 | 126 |
| BI, Low, BL, n=60, 127 | 0 | 0 |
| BI, High, Week 52/WD, n=56, 122 | 3 | 2 |
| BI, Normal, Week 52/WD, n=56, 122 | 53 | 120 |
| BI, Low, Week 52/WD, n=56, 122 | 0 | 0 |
| BT, High, BL, n=60, 127 | 6 | 5 |
| BT, Normal, BL, n=60, 127 | 54 | 122 |
| BT, Low, BL, n=60, 127 | 0 | 0 |
| BT, High, Week 52/WD, n=56, 122 | 6 | 3 |
| BT, Normal, Week 52/WD, n=56, 122 | 50 | 119 |
| BT, Low, Week 52/WD, n=56, 122 | 0 | 0 |
| CK, High, BL, n=60, 127 | 6 | 10 |
| CK, Normal, BL, n=60, 127 | 48 | 102 |
| CK, Low, BL, n=60, 127 | 6 | 15 |
| CK, High, Week 52/WD, n=56, 122 | 7 | 7 |
| CK, Normal, Week 52/WD, n=56, 122 | 44 | 92 |
| CK, Low, Week 52/WD, n=56, 122 | 5 | 23 |
| Chloride, High, BL, n=60, 127 | 1 | 0 |
| Chloride, Normal, BL, n=60, 127 | 58 | 124 |
| Chloride, Low, BL, n=60, 127 | 1 | 3 |
| Chloride, High, Week 52/WD, n=56, 122 | 2 | 6 |
| Chloride, Normal, Week 52/WD, n=56, 122 | 54 | 115 |
| Chloride, Low, Week 52/WD, n=56, 122 | 0 | 1 |
| CO2/BC, High, BL, n=60, 127 | 0 | 1 |
| CO2/BC, Normal, BL, n=60, 127 | 57 | 120 |
| CO2/BC, Low, BL, n=60, 127 | 3 | 6 |
| CO2/BC, High, Week 52/WD, n=56, 121 | 0 | 1 |
| CO2/BC, Normal, Week 52/WD, n=56, 121 | 48 | 116 |
| CO2/BC, Low, Week 52/WD, n=56, 121 | 8 | 4 |
| Creatinine, High, BL, n=60, 127 | 8 | 9 |
| Creatinine, Normal, BL, n=60, 127 | 50 | 115 |
| Creatinine, Low, BL, n=60, 127 | 2 | 3 |
| Creatinine, High, Week 52/WD, n=56, 122 | 6 | 10 |
| Creatinine, Normal, Week 52/WD, n=56, 122 | 47 | 108 |
| Creatinine, Low, Week 52/WD, n=56, 122 | 3 | 4 |
| GGT, High, BL, n=60, 127 | 9 | 25 |
| GGT, Normal, BL, n=60, 127 | 51 | 102 |
| GGT, Low, BL, n=60, 127 | 0 | 0 |
| GGT, High, Week 52/WD, n=56, 122 | 10 | 19 |
| GGT, Normal, Week 52/WD, n=56, 122 | 46 | 103 |
| GGT, Low, Week 52/WD, n=56, 122 | 0 | 0 |
| Glucose, High, BL, n=60, 127 | 16 | 58 |
| Glucose, Normal, BL, n=60, 127 | 43 | 65 |
| Glucose, Low, BL, n=60, 127 | 1 | 4 |
| Glucose, High, Week 52/WD, n=56, 122 | 26 | 56 |
| Glucose, Normal, Week 52/WD, n=56, 122 | 30 | 65 |
| Glucose, Low, Week 52/WD, n=56, 122 | 0 | 1 |
| Potassium, High, BL, n=60, 127 | 2 | 5 |
| Potassium, Normal, BL, n=60, 127 | 54 | 116 |
| Potassium, Low, BL, n=60, 127 | 4 | 6 |
| Potassium, High, Week 52/WD, n=56, 122 | 1 | 5 |
| Potassium, Normal, Week 52/WD, n=56, 122 | 53 | 111 |
| Potassium, Low, Week 52/WD, n=56, 122 | 2 | 6 |
| LDH, High, BL, n=60, 127 | 1 | 9 |
| LDH, Normal, BL, n=60, 127 | 59 | 116 |
| LDH, Low, BL, n=60, 127 | 0 | 2 |
| LDH, High, Week 52/WD, n=56, 122 | 4 | 10 |
| LDH, Normal, Week 52/WD, n=56, 122 | 52 | 111 |
| LDH, Low, Week 52/WD, n=56, 122 | 0 | 1 |
| Sodium, High, BL, n=60, 127 | 0 | 0 |
| Sodium, Normal, BL, n=60, 127 | 58 | 125 |
| Sodium, Low, BL, n=60, 127 | 2 | 2 |
| Sodium, High, Week 52/WD, n=56, 122 | 0 | 0 |
| Sodium, Normal, Week 52/WD, n=56, 122 | 55 | 120 |
| Sodium, Low, Week 52/WD, n=56, 122 | 1 | 2 |
| Urine pH, High, BL, n=60, 127 | 0 | 1 |
| Urine pH, Normal, BL, n=60, 127 | 60 | 126 |
| Urine pH, Low, BL, n=60, 127 | 0 | 0 |
| Urine pH, High, Week 52/WD, n=56, 122 | 0 | 0 |
| Urine pH, Normal, Week 52/WD, n=56, 122 | 56 | 122 |
| Urine pH, Low, Week 52/WD, n=56, 122 | 0 | 0 |
| USG, High, BL, n=60, 127 | 2 | 1 |
| USG, Normal, BL, n=60, 127 | 58 | 126 |
| USG, Low, BL, n=60, 127 | 0 | 0 |
| USG, High, Week 52/WD, n=56, 122 | 2 | 0 |
| USG, Normal, Week 52/WD, n=56, 122 | 54 | 122 |
| USG, Low, Week 52/WD, n=56, 122 | 0 | 0 |
| TP, High, BL, n=60, 127 | 1 | 3 |
| TP, Normal, BL, n=60, 127 | 55 | 118 |
| TP, Low, BL, n=60, 127 | 4 | 6 |
| TP, High, Week 52/WD, n=56, 122 | 1 | 3 |
| TP, Normal, Week 52/WD, n=56, 122 | 49 | 102 |
| TP, Low, Week 52/WD, n=56, 122 | 6 | 17 |
| Urea/BUN, High, BL, n=60, 127 | 5 | 13 |
| Urea/BUN, Normal, BL, n=60, 127 | 54 | 114 |
| Urea/BUN, Low, BL, n=60, 127 | 1 | 0 |
| Urea/BUN, High, Week 52/WD, n=56, 122 | 8 | 5 |
| Urea/BUN, Normal, Week 52/WD, n=56, 122 | 48 | 116 |
| Urea/BUN, Low, Week 52/WD, n=56, 122 | 0 | 1 |
| UA, High, BL, n=60, 127 | 13 | 22 |
| UA, Normal, BL, n=60, 127 | 46 | 102 |
| UA, Low, BL, n=60, 127 | 1 | 3 |
| UA, High, Week 52/WD, n=56, 122 | 13 | 23 |
| UA, Normal, Week 52/WD, n=56, 122 | 42 | 92 |
| UA, Low, Week 52/WD, n=56, 122 | 1 | 7 |
Urinalysis parameters included: Urine Occult Blood (UOB), Urine Glucose (UG), Urine Ketones (UK), Urine Protein (UP), and Urine Leukocyte Esterase test for detecting White Blood Cell (UWBC). The dipstick was a strip used to detect the presence or absence of these parameters in the urine sample. The dipstick test gives results in a semi-quantitative manner, and results can be read as negative (Neg), Trace, 1+, 2+, and 3+, indicating proportional concentrations in the urine sample. Data are reported as the number of participants who had neg, trace, 1+, 2+, and 3+ levels at Baseline (Week -2) and Week 52/WD.
| Participants | FF/VI 100/25 µg | FF/VI 200/25 µg |
|---|---|---|
| UOB, Neg, BL, n=60, 127 | 54 | 112 |
| UOB, Trace, BL, n=60, 127 | 4 | 6 |
| UOB, 1+, BL, n=60, 127 | 1 | 5 |
| UOB, 2+, BL, n=60, 127 | 1 | 2 |
| UOB, 3+, BL, n=60, 127 | 0 | 2 |
| UOB, Neg, Week 52/WD, n=56, 122 | 51 | 103 |
| UOB, Trace, Week 52/WD, n=56, 122 | 3 | 11 |
| UOB, 1+, Week 52/WD, n=56, 122 | 1 | 5 |
| UOB, 2+, Week 52/WD, n=56, 122 | 1 | 1 |
| UOB, 3+, Week 52/WD, n=56, 122 | 0 | 2 |
| UG, Neg, BL, n=60, 127 | 54 | 117 |
| UG, Trace, BL, n=60, 127 | 3 | 4 |
| UG, 1+, BL, n=60, 127 | 2 | 1 |
| UG, 2+, BL, n=60, 127 | 1 | 2 |
| UG, 3+, BL, n=60, 127 | 0 | 3 |
| UG, Neg, Week 52/WD, n=56, 122 | 49 | 109 |
| UG, Trace, Week 52/WD, n=56, 122 | 2 | 5 |
| UG, 1+, Week 52/WD, n=56, 122 | 3 | 1 |
| UG, 2+, Week 52/WD, n=56, 122 | 2 | 5 |
| UG, 3+, Week 52/WD, n=56, 122 | 0 | 2 |
| UK, Neg, BL, n=60, 127 | 60 | 127 |
| UK, Trace, BL, n=60, 127 | 0 | 0 |
| UK, 1+, BL, n=60, 127 | 0 | 0 |
| UK, 2+, BL, n=60, 127 | 0 | 0 |
| UK, 3+, BL, n=60, 127 | 0 | 0 |
| UK, Neg, Week 52/WD, n=56, 122 | 56 | 122 |
| UK, Trace, Week 52/WD, n=56, 122 | 0 | 0 |
| UK, 1+, Week 52/WD, n=56, 122 | 0 | 0 |
| UK, 2+, Week 52/WD, n=56, 122 | 0 | 0 |
| UK, 3+, Week 52/WD, n=56, 122 | 0 | 0 |
| UP, Neg, BL, n=60, 127 | 48 | 103 |
| UP, Trace, BL, n=60, 127 | 10 | 13 |
| UP, 1+, BL, n=60, 127 | 2 | 8 |
| UP, 2+, BL, n=60, 127 | 0 | 3 |
| UP, 3+, BL, n=60, 127 | 0 | 0 |
| UP, Neg, Week 52/WD, n=56, 122 | 41 | 92 |
| UP, Trace, Week 52/WD, n=56, 122 | 10 | 20 |
| UP, 1+, Week 52/WD, n=56, 122 | 4 | 8 |
| UP, 2+, Week 52/WD, n=56, 122 | 1 | 2 |
| UP, 3+, Week 52/WD, n=56, 122 | 0 | 0 |
| UWBC, Neg, BL, n=60, 127 | 58 | 120 |
| UWBC, Trace, BL, n=60, 127 | 0 | 0 |
| UWBC, 1+, BL, n=60, 127 | 1 | 6 |
| UWBC, 2+, BL, n=60, 127 | 0 | 1 |
| UWBC, 3+, BL, n=60, 127 | 1 | 0 |
| UWBC, Neg, Week 52/WD, n=56, 122 | 55 | 108 |
| UWBC, Trace, Week 52/WD, n=56, 122 | 0 | 0 |
| UWBC, 1+, Week 52/WD, n=56, 122 | 1 | 11 |
| UWBC, 2+, Week 52/WD, n=56, 122 | 0 | 3 |
| UWBC, 3+, Week 52/WD, n=56, 122 | 0 | 0 |
24-hour urinary cortisol excretion was calculated by multiplying the total volume of urine by the concentration of urinary cortisol. Cortisol is a hormone released from the adrenal gland that helps in fat, protein, and carbohydrate metabolism. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Nanomoles (nmol)/24 hours | FF/VI 100/25 µg | FF/VI 200/25 µg |
|---|---|---|
| Week 24, n=25, 43 | 1.0627 ± 76.135 | 0.8160 ± 55.926 |
| Week 52/WD, n=24, 41 | 0.8862 ± 37.078 | 0.8593 ± 52.770 |
Blood pressure measurement included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD. Blood pressure was measured in a sitting position after a participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Millimeters of Mercury (mmHg) | FF/VI 100/25 µg | FF/VI 200/25 µg |
|---|---|---|
| SBP, Week 4, n=58, 124 | 4.3 ± 12.05 | 1.2 ± 12.47 |
| SPB, Week 8, n=58, 123 | 2.5 ± 11.97 | 0.4 ± 13.33 |
| SPB, Week 12, n=57, 119 | 2.7 ± 14.88 | 1.2 ± 14.00 |
| SBP, Week 16, n=57, 116 | 1.2 ± 12.94 | 0.9 ± 14.18 |
| SBP, Week 24, n=53, 115 | -0.3 ± 13.20 | -1.3 ± 14.63 |
| SBP, Week 32, n=53, 112 | -1.8 ± 12.77 | -5.0 ± 14.76 |
| SBP, Week 40, n=50, 107 | -3.0 ± 13.65 | -3.9 ± 14.06 |
| SBP, Week 52, n=49, 106 | 3.7 ± 15.43 | 0.7 ± 15.16 |
| SBP, Week 24/WD, n=56, 125 | -0.9 ± 13.73 | -1.1 ± 14.48 |
| SBP, Week 52/WD, n=56, 123 | 2.4 ± 15.72 | 1.1 ± 15.82 |
| DBP, Week 4, n=58, 124 | 3.3 ± 9.07 | 0.9 ± 10.13 |
| DBP, Week 8, n=58, 123 | 0.1 ± 8.48 | 1.0 ± 9.55 |
| DBP, Week 12, n=57, 119 | 0.7 ± 8.09 | 0.8 ± 10.76 |
| DBP, Week 16, n=57, 116 | 0.4 ± 9.69 | 0.7 ± 10.76 |
| DBP, Week 24, n=53, 115 | 0.3 ± 9.30 | -1.1 ± 11.71 |
| DBP, Week 32, n=53, 112 | -1.6 ± 8.50 | -1.6 ± 11.23 |
| DBP, Week 40, n=50, 107 | -1.6 ± 8.89 | -0.3 ± 11.08 |
| DBP, Week 52, n=49, 106 | 1.2 ± 12.43 | 0.8 ± 10.77 |
| DBP, Week 24/WD, n=56, 125 | 0.2 ± 9.34 | -1.2 ± 11.42 |
| DBP, Week 52/WD, n=56, 123 | 0.8 ± 11.97 | 0.7 ± 11.29 |
Heart rate was measured in a sitting position after a participant was kept at rest for at least 5 minutes at assessment time points (Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Beats/Minute | FF/VI 100/25 µg | FF/VI 200/25 µg |
|---|---|---|
| HR, Week 4, n=58, 124 | 0.2 ± 9.84 | -0.3 ± 11.04 |
| HR, Week 8, n=58, 123 | -0.2 ± 11.41 | 0.3 ± 12.06 |
| HR, Week 12, n=57, 119 | -1.6 ± 9.37 | -0.1 ± 11.27 |
| HR, Week 16, n=57, 116 | 0.7 ± 9.50 | 1.5 ± 12.58 |
| HR, Week 24, n=53, 115 | -0.7 ± 10.69 | -1.1 ± 11.53 |
| HR, Week 32, n=53, 112 | -0.5 ± 9.23 | 0.1 ± 10.30 |
| HR, Week 40, n=50, 107 | 1.7 ± 9.66 | -0.3 ± 11.59 |
| HR, Week 52, n=49, 106 | 1.9 ± 9.32 | 1.1 ± 12.12 |
| HR, Week 24/WD, n=56, 125 | -1.1 ± 11.03 | -0.7 ± 11.43 |
| HR, Week 52/WD, n=56, 123 | 1.8 ± 10.62 | 2.0 ± 12.71 |
A 12-lead ECG was recorded in a supine position after the participant was kept at rest in this position for at least 5 minutes at assessment time points (Week 12, Week 24, and Week52). Data are presented for clinically significant (CS) as well as not clinically significant (NCS) abnormal findings. Any abnormal ECG, including those that worsen from baseline, and clinically significant as assessed by the investigator were recorded as CS.
| Participants | FF/VI 100/25 µg | FF/VI 200/25 µg |
|---|---|---|
| BL, CS, n=60, 127 | 0 | 0 |
| BL, NCS, n=60, 127 | 19 | 43 |
| Week 12, CS, n=57, 119 | 0 | 1 |
| Week 12, NCS, n=57, 119 | 17 | 37 |
| Week 24, CS, n=54, 115 | 0 | 0 |
| Week 24, NCS, n=54, 115 | 17 | 33 |
| Week 52, CS, n=49, 106 | 1 | 1 |
| Week 52, NCS, n=49, 106 | 14 | 35 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FF/VI 100/25 µg | — | 10/60 (16.7%) | 36/60 (60%) |
| FF/VI 200/25 µg | — | 23/127 (18.1%) | 93/127 (73.2%) |
| Event | FF/VI 100/25 µg | FF/VI 200/25 µg |
|---|---|---|
| PneumoniaInfections and infestations | 3/60 | 8/127 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/60 | 3/127 |
| BronchopneumoniaInfections and infestations | 1/60 | 0/127 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/60 | 1/127 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/60 | 0/127 |
| LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/60 | 0/127 |
| Inguinal herniaGastrointestinal disorders | 1/60 | 0/127 |
| Ventricular tachycardiaCardiac disorders | 1/60 | 0/127 |
| Age-related macular degenerationEye disorders | 1/60 | 0/127 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/60 | 2/127 |
| Event | FF/VI 100/25 µg | FF/VI 200/25 µg |
|---|---|---|
| NasopharyngitisInfections and infestations | 18/60 | 54/127 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 8/60 | 12/127 |
| Back painMusculoskeletal and connective tissue disorders | 4/60 | 13/127 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 6/60 | 8/127 |
| BronchitisInfections and infestations | 5/60 | 8/127 |
| Oral candidiasisInfections and infestations | 0/60 | 10/127 |
| PharyngitisInfections and infestations | 4/60 | 7/127 |
| EczemaSkin and subcutaneous tissue disorders | 4/60 | 6/127 |
| PneumoniaInfections and infestations | 1/60 | 8/127 |
| ConstipationGastrointestinal disorders | 3/60 | 4/127 |
| Age, Continuous(Years) | FF/VI 100/25 µg | FF/VI 200/25 µg | Total |
|---|---|---|---|
| Mean | 69.5 ± 7.66 | 71.0 ± 7.39 | 70.5 ± 7.49 |
| Gender(Participants) | FF/VI 100/25 µg | FF/VI 200/25 µg | Total |
|---|---|---|---|
| Female | 2 | 11 | 13 |
| Male | 58 | 116 | 174 |
| Race/Ethnicity, Customized(Participants) | FF/VI 100/25 µg | FF/VI 200/25 µg | Total |
|---|---|---|---|
| Asian - Japanese Heritage | 60 | 127 | 187 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Aug 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 1 year 7 months after primary completion. A results delay was requested in Mar 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →